Everything That Changes on 1 October 2026: A Compliance Countdown for Canadian Licence Holders

On 1 October 2026, six separate regulatory instruments take effect on the same day. If you hold a Health Canada licence for cannabis, drugs, natural health products or medical devices, at least one of them almost certainly applies to you, and several may apply at once. This article is a countdown. It sets out, in one place, what changes on 1 October, what changes in the days just before it, and what a licence holder should do about each item before the date arrives.

We have published full articles on most of these instruments. This page is the map that ties them together. Each section gives you the short version and a direct answer, then points you to the detailed guidance. The time left, however many days it is when you read this, is enough to close a gap you already know about. It is not enough to find one you do not.

Executive Summary

Six instruments come into force on 1 October 2026: the Controlled Substances Regulations (SOR/2025-242), the cannabis harmonization amendments (SOR/2025-244), Health Canada's revised foreign action notification list under section C.01.050, Health Canada's updated summary reports guidance, PIC/S PI 006-4 on qualification and validation, and the United States Food and Drug Administration priority review voucher fee for fiscal year 2027. Five further deadlines fall in the run-up, from 20 September to 30 September. The single most important cannabis deadline of the group, the annual regulatory fee and the medical-sale exemption declaration, is due on 30 September, and Health Canada must refuse a late declaration. Treat 1 October as a hard line and work backward from it.

What Changes on 1 October 2026?

In short: six instruments take effect on 1 October 2026, spanning controlled substances, cannabis, pharmaceutical post-market reporting, validation practice and cross-border user fees. The table below is the at-a-glance version. Each row is expanded in its own section, with a link to the detailed article.

Cannabis and Controlled Substances: SOR/2025-244 and SOR/2025-242

What it is: the Controlled Substances Regulations (SOR/2025-242) consolidate several older regulatory schemes into one modernized framework, and the cannabis amendments (SOR/2025-244) align the Cannabis Regulations with that framework. Both come into force on 1 October 2026. SOR/2025-244 was registered on 28 November 2025 and published in the Canada Gazette, Part 2, on 17 December 2025, so the text has been available for months and the in-force date is fixed.

Why it matters: harmonization means your cannabis standard operating procedures, security controls and record-keeping have to reflect the new controlled substances language, not the old one. For a section-by-section view of the cannabis changes, see our guide to every SOR/2025-244 cannabis change in force 1 October 2026, and for the dealer and manufacturer side, read what the new Controlled Substances Regulations (SOR/2025-242) mean for manufacturers and dealers.

What to do: reconcile your SOPs, quality agreements and security procedures against both instruments now. Confirm that references to superseded regulations are updated, that your quality assurance person has reviewed the changes, and that staff who handle controlled substances or cannabis have been retrained before the date, not after.

Health Canada Summary Reports: The Submission Trigger Changes

What it is: Health Canada's updated summary reports guidance takes effect on 1 October 2026 for drug identification number and natural product number holders. The duty to prepare a summary report on a defined cycle does not go away. What changes is the trigger for when you must submit that report to Health Canada. The obligation to keep the analysis current is unchanged, so a holder who reads the update as a reason to stop preparing reports has misread it. Our full explainer covers what DIN and NPN holders must change under the summary reports guidance.

Why it matters and what to do: a summary report is a signal-detection document, and inspectors look for evidence that the review actually happened on schedule. Confirm your standard operating procedure names the correct preparation cycle, that the responsible person is assigned, and that the submission trigger in your SOP matches the new guidance. Do not let the change in submission mechanics erode the underlying pharmacovigilance discipline.

The Foreign Action Notification List Shrinks: C.01.050

What it is: the list of foreign regulatory authorities whose actions you must notify Health Canada about, under section C.01.050 of the Food and Drug Regulations, is being reduced from 41 authorities across 35 jurisdictions to 22 authorities across 13. A shorter list does not mean a lighter duty. It means the set of triggering authorities has been redefined, and your internal notification procedure has to match the new set exactly. See our detailed piece on the foreign action notification list moving from 41 authorities to 22.

What to do: update the authority list embedded in your foreign-action reporting SOP so it reflects the 22 recognized authorities. If your procedure simply says "the authorities on the Health Canada list", confirm your staff know where the current list lives and check it on the effective date, because Health Canada may adjust how the list is published when it goes live.

PIC/S PI 006-4: Qualification and Validation, Rewritten

What it is: PIC/S PI 006-4, the recommendation on qualification and validation, enters into force on 1 October 2026 and replaces PI 006-3, which dated from September 2007. The new single document folds in the concepts introduced when Annex 15 was revised in 2015, with quality risk management under ICH Q9 running through every section. It adds prequalification stages, performance qualification, ongoing process verification, transport verification, packaging validation, utility qualification and test method validation, and it treats qualification and validation as lifecycle activities scaled by risk. The recommendation is published by PIC/S.

Why it matters and what to do: inspectors from PIC/S participating authorities, including Health Canada, will apply the modernized expectations. Review your validation master plan against the lifecycle structure, confirm your risk rationales are documented rather than assumed, and check that ongoing process verification is a live programme and not a one-time exercise. This change sits alongside the EU GMP updates we track, including the revised Annex 19 on reference and retention samples.

FDA Priority Review Voucher Fee for FY2027

What it is: the United States FDA has set the priority review voucher fee for fiscal year 2027 at $1,798,596. The rate is effective on 1 October 2026 and remains in effect through 30 September 2027. It applies to any eligible human drug or biological product application received on or after 1 October 2026 that is submitted with a tropical disease, rare pediatric disease or material threat medical countermeasure voucher, and it is payable in addition to the normal user fee. The FDA notice states the amount and dates in the Federal Register.

Why it matters and what to do: the fee binds any sponsor, including Canadian companies, that intends to redeem a voucher in a United States application. There is no waiver, exemption, reduction or refund available for this fee. If a submission using a voucher is realistic in your FY2027 planning, budget the amount now and align it with the 90-day notification-of-intent requirement that precedes the application.

The September Run-Up: Five More Dates Before 1 October

Why it matters: 1 October is not the only date that matters. Five deadlines land in the ten days before it, and one of them, the cannabis annual regulatory fee, carries a mandatory refusal if you miss it. Plan the whole run-up, not just the headline date.

The 30 September cannabis deadline is the one to protect first. Health Canada must refuse a late medical-sale exemption declaration, so the filing window is unforgiving. Our guide to the cannabis annual regulatory fee and the medical exemption declaration walks through the CTLS steps. For the two device and NHP items, see our coverage of the draft NHP Quality Guide version 4 and the recognized standards list going continuous.

1 October 2026 Compliance Checklist

Use this list to confirm which items apply to your licence and whether each is covered before the date.

• Cannabis and controlled substances SOPs updated to reflect SOR/2025-242 and SOR/2025-244.
• Staff who handle controlled substances or cannabis retrained on the harmonized requirements before 1 October.
• Summary report SOP checked against the new preparation cycle and submission trigger for your DIN or NPN products.
• Foreign-action reporting procedure updated to the revised list of 22 recognized authorities under C.01.050.
• Validation master plan and ongoing process verification reviewed against PIC/S PI 006-4.
• FY2027 priority review voucher fee of $1,798,596 budgeted if a US voucher submission is planned.
• Cannabis annual regulatory fee and medical-sale exemption declaration filed through CTLS on or before 30 September.
• Reference and retention sample procedures aligned with EudraLex Annex 19 by 24 September, if you supply the EU market.
• Import admissibility of any US-bound dairy, whey, molasses or non-alcoholic beer reviewed before 29 September.

Common Mistakes

• Reading a shorter foreign-action list as a lighter duty. The set of triggering authorities changed; the obligation to notify did not.
• Treating the summary reports change as permission to stop preparing reports. The duty to prepare and keep the analysis current is unchanged.
• Waiting until 1 October to retrain staff. Training that lands after the effective date is a finding waiting to happen.
• Missing the 30 September cannabis fee window. A late medical-sale exemption declaration must be refused, so there is no grace period to lean on.
• Assuming PI 006-4 is a light edit of PI 006-3. It is a full rewrite with new lifecycle stages and a risk-based structure.

Frequently Asked Questions

When does SOR/2025-244 come into force?

SOR/2025-244, the cannabis harmonization amendments, comes into force on 1 October 2026. It was registered on 28 November 2025 and published in the Canada Gazette, Part 2, on 17 December 2025. The related Controlled Substances Regulations, SOR/2025-242, come into force on the same date.

What happens if I miss the cannabis annual fee deadline?

The cannabis annual regulatory fee and the medical-sale exemption declaration are due through the Cannabis Tracking and Licensing System by 30 September 2026. Health Canada must refuse a late exemption declaration, which means a missed filing can expose you to the full annual fee. File early and keep proof of submission.

Is the EU GMP Annex 19 in force yet?

The revised EudraLex GMP Annex 19 on reference and retention samples becomes applicable on 24 September 2026 under Commission decision C(2026) 4135. Manufacturers that hold reference and retention samples for the EU market should align their procedures before that date.

What is the FDA priority review voucher fee for 2027?

The FDA priority review voucher fee for fiscal year 2027 is $1,798,596. It is effective on 1 October 2026 and remains in effect through 30 September 2027, and it applies to any eligible application received on or after 1 October 2026 that uses a voucher. There is no waiver, exemption or refund for this fee.

How is PIC/S PI 006-4 different from PI 006-3?

PI 006-4 is a complete rewrite that replaces the 2007 PI 006-3. It reflects the 2015 revision of Annex 15, embeds quality risk management under ICH Q9, and adds prequalification, performance qualification, ongoing process verification, transport verification, packaging validation, utility qualification and test method validation as lifecycle activities scaled by risk. It comes into force on 1 October 2026.

Which Canadian products are banned from US import from 29 September 2026?

Under Proclamation 11062, a list of Canadian goods including whey products, molasses products and non-alcoholic beer is excluded from importation into the United States starting at 12:01 a.m. eastern on 29 September 2026, using authority under section 338 of the Tariff Act of 1930. Goods imported but not yet entered for consumption before that time remain subject to the existing 50 percent duty rather than the ban. Canadian food exporters should complete an import-admissibility review before the date.

How MFLRC Can Help

MFLRC helps regulated companies turn a countdown like this into a plan. We run a gap assessment against the full 1 October cluster and tell you, in writing, which instruments apply to your licence and what is missing. We update SOPs and documentation, prepare summary reports, support CTLS filing for the cannabis fee and exemption declaration, and provide quality assurance person services and inspection-readiness reviews. Explore our regulatory affairs, licensing and import and export services, our audit services, and our cannabis and hemp support.

The time left is enough to close a gap and not enough to find one. Book a 1 October readiness assessment and we will tell you which of these apply to your licence and what to fix first.

Conclusion

1 October 2026 is a rare convergence: six instruments, four sectors, one date, with five more deadlines crowded into the ten days before it. None of them is unmanageable on its own. The risk is that a licence holder tracks one and misses the others, or discovers on 30 September that a filing needed to happen weeks earlier. Map your exposure now, work backward from the date, and protect the 30 September cannabis window first. A countdown is only useful while there is still time on the clock.

Sources and References

• Canada Gazette, Part 2: Regulations Amending the Cannabis Regulations (SOR/2025-244)
• Justice Laws Website: Controlled Substances Regulations (SOR/2025-242)
• US Federal Register: Fee Rate for Using a Priority Review Voucher in Fiscal Year 2027 (91 FR 57617)
• PIC/S: PI 006-4 Recommendations on Qualification and Validation
• Health Canada guidance on summary reports and the foreign action notification list (section C.01.050 of the Food and Drug Regulations)